Saltar al contenido
Salud cardiovascularEnsayo aleatorizado3 min read

Evening vs morning blood pressure pills: no difference in heart outcomes

Colectivo editorial MoveVitals · Study published · Reading updated

Original paper:Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK (TIME study): a prospective, randomised, open-label, blinded-endpoint clinical trial. · Lancet (London, England) · 2022 · Artículo original ↗

Idea principal

In 21 104 UK adults with hypertension followed a median 5.2 years, major cardiovascular events occurred in 3.4% on evening dosing and 3.7% on morning dosing (hazard ratio 0.95; 95% CI 0.83-1.10; p=0.53). The trial was open-label, with events found partly by participant report, and more people withdrew from the evening group.

Study design

Ensayo aleatorizado

Reading basis

Published abstract

Reading focus

Comparator & uncertainty

Esta explicación editorial está disponible en inglés, chino simplificado y chino tradicional. Esta interfaz muestra la lectura en inglés.

Pregunta de investigación

Earlier studies suggested that taking blood pressure medicines at bedtime might protect the heart better than taking them in the morning, but this was not settled. The authors tested in the TIME study whether taking usual antihypertensive medication in the evening reduces major cardiovascular outcomes compared with the morning.

Población y método

TIME was a prospective, pragmatic, decentralised, parallel-group, randomised, open-label, blinded-endpoint trial in the UK of adults aged 18 or older with hypertension taking at least one antihypertensive medication. Between Dec 17, 2011 and June 5, 2018, 21 104 were randomly assigned 1:1 to take all their usual antihypertensives in the morning (0600-1000 h) or evening (2000-0000 h). The primary endpoint was vascular death or hospitalisation for non-fatal myocardial infarction or non-fatal stroke, analysed as time to first event in the intention-to-treat population. Endpoints came from participant report or NHS record linkage and were adjudicated by a committee masked to allocation. Funded by the British Heart Foundation; registered with EudraCT and ISRCTN.

Resultados

The authors’ reported results. Read each estimate with its population and uncertainty.

  1. 1
    Of 21 104 randomised, 10 503 were assigned to evening and 10 601 to morning dosing (mean age 65.1 years; 57.5% men; median follow-up 5.2 years).
  2. 2
    A primary endpoint event occurred in 362 (3.4%) evening participants (0.69 events per 100 patient-years) and 390 (3.7%) morning participants (0.72 per 100 patient-years); unadjusted hazard ratio 0.95 (95% CI 0.83-1.10; p=0.53), a null result.
  3. 3
    No safety concerns were identified. The authors conclude patients can take usual medicines at a convenient time that minimises undesirable effects.

Límites e incertidumbre

  1. 1
    The open-label design means participants knew their timing; events were identified partly by self-report, though adjudicators were masked.
  2. 2
    More participants withdrew from all follow-up in the evening group (529, 5.0%) than the morning group (318, 3.0%).
  3. 3
    Participants were 90.5% White and mean age 65.1 years, so results may not apply equally to other groups.
  4. 4
    This reading is based on the abstract only, and the abstract does not report effects in subgroups.

Relevancia práctica

If you take blood pressure medicine, this large trial found no heart-protection advantage for either morning or evening dosing, so choosing the time that you will remember and tolerate best is reasonable. Any change in when or how you take your medicine should be agreed with your clinician or pharmacist.

Tus datos

A home cuff can show how your blood pressure behaves across the day, which can help your clinician judge whether timing suits you. Measure at the same times, in the same posture and with the same device, and look at the average of several readings rather than a single number.

Cómo interpretar la evidencia

Randomisation can support causal inference, but check allocation, blinding, missing outcomes, follow-up and the actual comparator. A trial label alone does not establish high certainty.

Resumen estructurado de los autores English

El resumen original en inglés se reproduce con atribución bajo la licencia indicada. Es una fuente, no una interpretación de MoveVitals. El análisis preparado figura arriba; verifica los resultados importantes en la fuente.

Background

Studies have suggested that evening dosing with antihypertensive therapy might have better outcomes than morning dosing. The Treatment in Morning versus Evening (TIME) study aimed to investigate whether evening dosing of usual antihypertensive medication improves major cardiovascular outcomes compared with morning dosing in patients with hypertension.

Methods

The TIME study is a prospective, pragmatic, decentralised, parallel-group study in the UK, that recruited adults (aged ≥18 years) with hypertension and taking at least one antihypertensive medication. Eligible participants were randomly assigned (1:1), without restriction, stratification, or minimisation, to take all of their usual antihypertensive medications in either the morning (0600-1000 h) or in the evening (2000-0000 h). Participants were followed up for the composite primary endpoint of vascular death or hospitalisation for non-fatal myocardial infarction or non-fatal stroke. Endpoints were identified by participant report or record linkage to National Health Service datasets and were adjudicated by a committee masked to treatment allocation. The primary endpoint was assessed as the time to first occurrence of an event in the intention-to-treat population (ie, all participants randomly assigned to a treatment group). Safety was assessed in all participants who submitted at least one follow-up questionnaire. The study is registered with EudraCT (2011-001968-21) and ISRCTN (18157641), and is now complete.

Findings

Between Dec 17, 2011, and June 5, 2018, 24 610 individuals were screened and 21 104 were randomly assigned to evening (n=10 503) or morning (n=10 601) dosing groups. Mean age at study entry was 65·1 years (SD 9·3); 12 136 (57·5%) participants were men; 8968 (42·5%) were women; 19 101 (90·5%) were White; 98 (0·5%) were Black, African, Caribbean, or Black British (ethnicity was not reported by 1637 [7·8%] participants); and 2725 (13·0%) had a previous cardiovascular disease. By the end of study follow-up (March 31, 2021), median follow-up was 5·2 years (IQR 4·9-5·7), and 529 (5·0%) of 10 503 participants assigned to evening treatment and 318 (3·0%) of 10 601 assigned to morning treatment had withdrawn from all follow-up. A primary endpoint event occurred in 362 (3·4%) participants assigned to evening treatment (0·69 events [95% CI 0·62-0·76] per 100 patient-years) and 390 (3·7%) assigned to morning treatment (0·72 events [95% CI 0·65-0·79] per 100 patient-years; unadjusted hazard ratio 0·95 [95% CI 0·83-1·10]; p=0·53). No safety concerns were identified.

Interpretation

Evening dosing of usual antihypertensive medication was not different from morning dosing in terms of major cardiovascular outcomes. Patients can be advised that they can take their regular antihypertensive medications at a convenient time that minimises any undesirable effects.

Funding

British Heart Foundation.

Fuentes y atribución

Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK (TIME study): a prospective, randomised, open-label, blinded-endpoint clinical trial.

Mackenzie IS, Rogers A, Poulter NR, Williams B, Brown MJ, Webb DJ, Ford I, Rorie DA, Guthrie G, Grieve JWK, Pigazzani F, Rothwell PM, Young R, McConnachie A, Struthers AD, Lang CC, MacDonald TM, TIME Study Group.

Lancet (London, England) · 2022-10-11

DOI: 10.1016/s0140-6736(22)01786-x ↗PubMed · 36240838 ↗Europe PMC · Licencia registrada: cc by ↗

Abstract © the original authors, reproduced under the recorded open licence. Translations support reading; use the English record to check terminology and numerical results. Our methodological interpretation is separate from the authors’ conclusions.

Interpretación editorial de MoveVitals · contenido educativo · sin revisión clínica individual registrada

Fuentes verificadas 2026-11-01

Guías prácticas

Leer en contexto

·Metaanálisis observacional

Disrupted daily rest-activity rhythm is linked to higher mortality in 109,365 people

Across seven observational studies with 109,365 participants, a weaker day-night activity contrast (lower relative amplitude) was associated with higher cardiovascular mortality (hazard ratio [HR] 1.50, 95% CI 1.13 to 1.98) and all-cause mortality (HR 1.46, 95% CI 1.27 to 1.68). The evidence base is small and observational, so it cannot show that improving the rhythm lowers risk, and illness may itself disturb the rhythm.

Journal of the American Heart Association

Explicaciones detalladasLeer estudio →
·Metaanálisis de ensayos

Five exercise types lowered resting blood pressure, isometric training the most

Pooling 270 randomised trials with 15,827 participants, aerobic, resistance, combined, interval and isometric training all lowered resting blood pressure compared with non-intervention controls (P<0.001 for each), with the largest fall for isometric training: 8.24 mm Hg systolic and 4.00 mm Hg diastolic. The ranking between modes is partly indirect and the trials differ, so it is not a personal prescription.

British Journal of Sports Medicine

Explicaciones detalladasLeer estudio →
·Ensayo aleatorizado

A salt substitute lowered stroke, major cardiovascular events and death in rural China

In 20,995 people in 600 rural Chinese villages who had a history of stroke or were 60 or older with high blood pressure, a salt substitute (75% sodium chloride, 25% potassium chloride) lowered the stroke rate versus regular salt over a mean 4.74 years: 29.14 versus 33.65 events per 1000 person-years (rate ratio 0.86, 95% CI 0.77 to 0.96; P = 0.006). Death was also lower (rate ratio 0.88) and serious hyperkalemia events were not significantly higher, but the trial was open-label and set in rural China.

The New England Journal of Medicine

Explicaciones detalladasLeer estudio →
·Estudio/revisión de validación

Apple Watch irregular-pulse alerts were rare; 34% of those tested had atrial fibrillation

Among 419,297 Apple Watch users with no known atrial fibrillation (AF), 0.52% received an irregular-pulse alert, and 34% of the 450 who returned a usable ECG patch had AF (97.5% CI 29 to 39). Alerts that coincided with patch recording matched AF with a positive predictive value of 0.84 (95% CI 0.76 to 0.92), but only 20.8% of alerted people returned a patch and nobody without an alert was monitored, so a quiet watch does not rule AF out.

The New England Journal of Medicine

Explicaciones detalladasLeer estudio →
Salud cardiovascular →